Replies to post #152155 on Strategic Asset Leasing Inc (LEAS)

[Zardiw]

Guy seems to have legitimate questions.......fwiw.......

Z

[Zardiw]

Why $LEAS Shares are really worth .057:

These are excerpts from the S4 filed by $RWOD a few days ago on 8-4-23:

Target compliance ready. ANEW was currently trading on the OTC Markets under the symbol “LEAS”, and its filings were up to date.

Based on the fact that the $60,000,000 fair market value of ANEW as described above.

As a result of the Business Combination Agreement, former stockholders of ANEW will receive an aggregate of 6,000,000 shares of Redwoods common stock.

LEAS Outstanding Shares is 1,045,000,000.

SO if you divide 1,045,000,000 by the 6,000,000 shares of Redwood shares, you get 174 LEAS Shares for every Redwood Share.

Those 174 LEAS shares are currently worth 174 x .0049 = .85.

Redwood shares are valued at $10/share.

SO, $10 worth of Redwood is currently trading at .85 of LEAS Shares!!

10/.85 = 11.7 Bagger.

Also, $10 divided by 174 = .057/share which is the True Value of LEAS shares!

ANEW stockholders will have a relative majority of the voting power of the Combined Company;

ANEW’s senior management will comprise the senior management roles of the Combined Company and be responsible for the day-to-day operations; and

• The Combined Company will assume the ANEW name.

Following the consummation of the Transactions, Redwoods will change its name to Anew Medical, Inc. The new public entity following the consummation of the Transactions is referred to herein as the “Combined Company.”

Redwoods will acquire all of the outstanding equity interests of ANEW in exchange for shares of Redwoods’ common stock, par value $0.0001 per share (the “Common Stock”), based on an implied ANEW equity value of $60,000,000 (the “Merger Consideration”) valued at $10 per share, to be paid to ANEW stockholders at the effective time of the Merger.

Redwoods has applied to have Redwood Common Stock and warrants listed on The Nasdaq Stock Market LLC (“Nasdaq”), and it will change its name to Anew Medical, Inc.

As a result, Redwoods believes that a business combination with ANEW will provide Redwoods stockholders with an opportunity to participate in the ownership of a company with significant growth potential.

ANEW stockholders will own 6,000,000 shares of the combined company. Stockholders of ANEW are expected to own approximately 34.0% of the issued and outstanding shares of Redwoods Common Stock


At or prior to the Effective Time, Redwoods will instruct the Exchange Agent to issue to each shareholder of ANEW the portion of the Merger Consideration to which that shareholder of ANEW is entitled pursuant to the Business Combination Agreement at or promptly after the Closing.

Advantage: Low Target Equity Value. The Redwoods Board was presented with the pre-money valuation at IPO and current market capitalization for each of the selected public comparable companies of ANEW: Voyager Therapeutics (VYGR), Passage Bio (PASG), Taysha Gene Therapies (TSHA), Homology Medicines (FIXX), Abeona Therapeutics (ABEO), Aclaris Therapeutics (ACRS), Sol-Gel Technologies (SLGL) and Novan (NOVN). The average pre-money valuation at IPO for these peer companies was $326 million, with a low end of $123 million and a high end of $576 million, and the average current market capitalization forthese peer companies was $172 million, with a low end of $35 million and a high end of $582 million. The final negotiated transaction consideration for ANEW was $60 million, the rationale behind Redwoods’ accepting this valuation was:

• after taking into consideration the average pre-money valuation at IPO and the average current market capitalization, a transaction consideration below $100 million would be appropriate for a company like ANEW; and

• the low transaction valuation provides more potential upside potentials for investors.

What is ANEW?

ANEW MEDICAL, INC., a Wyoming corporation, is dedicated to realizing the potential of biologic, cell and gene therapies to offer transformative patient outcomes in areas of high unmet medical need by extending the reach of protein, cell, and gene therapies to highly prevalent neurodegenerative disorders like amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease as they are universally fatal neurodegenerative diseases.

We have assembled a portfolio of gene therapy candidates in partnership with leading scientific institutions and have built a team with extensive experience in the biotechnology commercialization and gene therapy space. Our team will pursue new innovations in vector design and delivery to optimize our investigational gene therapy products for safety, potency, durability, and clinical response. We plan on building integrated internal development capabilities from product development through commercialization and focus on accelerating the pace of product development in the clinic. In addition, as part of our ongoing business strategy, we continue to explore potential opportunities to acquire or license new product candidates as well as opportunities for partnership or collaboration on our existing products in development.

Executive Officers

Joseph Sinkule — Dr. Sinkule has evolved from a chemist, scientist and clinical researcher into a successful businessman and serial entrepreneur. He received his B.S. in Chemistry from the University of Nebraska in 1976 and a doctorate in pharmacy, pharmacology and pharmacokinetics (Pharm.D.) from University of Nebraska Medical Center in 1980. His post-doctoral training was at St. Jude Children’s Research Hospital in Memphis, TN and he held several academic positions at the University of Chicago and the University of Michigan. He joined the pharmaceutical and biotechnology industry in 1990 and held key management and senior directorship positions for over 15 years including Senior Vice President and Board member of Techniclone International, a Nasdaq-listed biotech company at the age of 33 years old. He founded, was the CEO, and served on the Board of two biopharmaceutical companies — Virionics Corporation from 2005-2008 and Apthera, Inc. from 2008-2012. He founded and served as CEO and Chairman of the Board of Anew Oncology, Inc. in 2015, which became ANEW MEDICAL, INC. in 2019. Joseph has been involved with drug development for the past 40 years. He has been a consultant and advisor to several companies and academics in the fields of cell and gene therapy for the past 18 years. Dr. Sinkule is also the Chair of the Corporate Governance Committee. Dr. Sinkule is qualified to serve on our Board of Directors due to his extensive management experience, drug development experience, business, finance, and entrepreneurial experiences, as well as his international contacts and relationships.

David Sandor, Ph.D. - Dr. Sandor‘s experience spans 18 years in the pharmaceutical industry at Schering-Plough and Hoffman-LaRoche Pharmaceuticals, years in academia as Associate Dean and Professor at Touro College of Pharmacy, Touro College of Medicine, and as an entrepreneur for the past 12 years as President and founder of his own healthcare company, Genesis Health Outcomes Research Corporation. He graduated from Adelphi University with Honors, and obtained a B.A., Masters, and Doctorate in Sociology and Social Welfare. Dr. Sandor’s extensive experience in the pharmaceutical and healthcare industries makes his suitable to serve as a director.

Peter Moriarty — Mr. Moriarty has extensive experience in the pharmaceutical industry both in the United States and internationally. He was a co-founder of Shire Pharmaceuticals, an international specialty pharmaceutical company acquired by Takeda Pharmaceuticals (TAK — NASDAQ). He was also the co-founder of Prismic Pharmaceuticals, where he was Chairman and Chief Executive from 2013 to 2018 and then, as Executive Chairman, led the company’s acquisition by FSD Pharma (HUGE — Nasdaq) in 2019. Peter’s earlier career spanned management positions within Warner-Lambert/Parke-Davis and Schering-Plough, including leadership positions overseas as well as in the United States. Additionally, he led the Sales Force Automation and Software Products Division at Walsh America (acquired by NDC), and led Corporate Development at Ixsys/Applied Molecular Evolution acquired by Eli Lilly (LLY — NYSE). He was subsequently the founder, Chairman and Chief Executive Officer of iPhysicianNet, Inc. and Clinical Information Network. Mr. Moriarty attended Aston University School of Law in conjunction with his training to become a Solicitor (Attorney) under the rules and regulations of the British Law Society 5-year Articles program. He passed the Final/Qualifying examinations in Contract Law (with distinction), Criminal Law, Tortious Law, and English Legal System (US accredited as equivalent to a Masters’ Degree).

https://www.sec.gov/ix?doc=/Archives/edgar/data/1907223/000121390023063756/fs42023_redwoodsacq.htm#T29

Z

[StockStud22]

You need to calm down and lay off. These are legitimate questions that people are asking for the most part.